SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 25, 2009--
Exelixis, Inc. (Nasdaq:EXEL) will release its fourth quarter and full
year 2008 financial results on Wednesday, March 4, 2009 after the
markets close. The announcement will be followed by a live webcast at
5:00 p.m. ET/ 2:00 p.m. PT, in which Exelixis management will discuss
the financial results and the company’s financial outlook, and will
provide a general business update. The webcast may be accessed in the
Event Calendar page under Investors at www.exelixis.com.
An audio replay of the webcast will be available until 11:59 p.m ET/
8:59 p.m. PT on April 4, 2009. Access numbers for the replay are:
1-888-286-8010 (domestic) and 1-617-801-6888, and the passcode is
34143616.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to
the discovery and development of novel small molecule therapeutics for
the treatment of cancer and other serious diseases. The company is
leveraging its fully integrated drug discovery platform to fuel the
growth of its development pipeline, which is primarily focused on
cancer. Currently, Exelixis’ broad product pipeline includes
investigational compounds in phase 3, phase 2, and phase 1 clinical
development. Exelixis has established strategic corporate alliances with
major pharmaceutical and biotechnology companies, including
Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Wyeth Pharmaceuticals,
and Daiichi-Sankyo. For more information, please visit the company’s web
site at www.exelixis.com.
Source: Exelixis, Inc.
Exelixis, Inc.
Investor Contact:
Charles
Butler, 650-837-7277
Senior Director, Corporate
Communications
cbutler@exelixis.com
Media
Contact:
Soleil Maxwell Harrison, 650-837-7012
Senior
Manager, Corporate Communications
sharrison@exelixis.com